Diabetes News

Researchers estimate that semaglutide 2.4 mg is not cost-effective for secondary CVD prevention for patients with overweight or obesity without diabetes, according to an Australian study.

Care partners of deaf and hard-of-hearing people with diabetes face several communication-related challenges that could be addressed through a specialized training program, according to two presenters.

GLP-1 receptor agonist use on top of SGLT2 inhibition in patients with HF with preserved ejection fraction, type 2 diabetes and obesity was associated with reduced risk for adverse events vs. SGLT2 inhibition alone, researchers reported.

Primary care practices can successfully implement continuous glucose monitoring for patients with diabetes by using American Academy of Family Physicians resources or a virtual CGM initiation service, according to two speakers.

Asian American, Native Hawaiian and Pacific Islander, or AA and NH/PI, communities continue to face significant racial disparities in health care access and outcomes across the United States, according to an expert.

The FDA has cleared an automated insulin delivery system for adults aged 18 years and older with type 2 diabetes, Insulet Corp. announced.

SGLT2 inhibitors and dulaglutide confer a similar risk for dementia among adults aged 60 years and older with type 2 diabetes, according to findings published in Annals of Internal Medicine.

High BMI eligibility for semaglutide could cost Medicare up to $145 billion annually, a brief report published in the Annals of Internal Medicine revealed.

More than half of patients with diabetes undergoing kidney biopsy had additional findings other than diabetic kidney disease, according to published data from the Cleveland Clinic Florida.

Preexisting diabetes was associated with a more than tripled odds of experiencing stillbirth or perinatal mortality, with higher risks for mothers with type 2 vs. type 1 diabetes, researchers reported in Obstetrics & Gynecology.